How did Stryker's Medsurg and Neurotechnology segment perform in Q4 2024?

Stryker's MedSurg and Neurotechnology segment likely performed well in Q4 2024, considering the overall positive trends and performance indicators for the company. 1. **Strong Performance Indicators**: Stryker has demonstrated robust performance in its MedSurg and Neurotechnology segments, with a strong product portfolio and a focus on innovation. The company's organic sales growth for the full year 2024 was raised to between 9.5% and 10.0%, up from the previous guidance. This indicates a strong demand for Stryker's products, which includes the MedSurg and Neurotechnology segments. 2. **Market Position and Growth Potential**: Stryker's strategic growth initiatives and focus on innovation position it well to capitalize on market opportunities. The company's flagship product, the Mako Total Knee Platform, has been a significant driver of growth, and strong customer demand for existing products and new launches suggests continued performance in Q4 2024. 3. **Financial Outlook**: Stryker's financial outlook for the year 2024 is positive, with an expected earnings per share (EPS) range of $12.00 to $12.10. This suggests that the MedSurg and Neurotechnology segment, along with the overall company, is on track to meet its financial targets. 4. **Comparative Performance**: Stryker's stock performance has outpaced the iShares U.S. Medical Devices ETF in both the year-to-date and past 52-week periods. This indicates a strong market confidence in the company's performance, which likely reflects positively on the MedSurg and Neurotechnology segment. While specific revenue figures for the MedSurg and Neurotechnology segment in Q4 2024 are not available, the overall positive performance indicators and market positioning of Stryker suggest that this segment likely performed well during the quarter.